[1]
|
陈运彬. 特殊状态儿童预防接种(广东)专家共识[J]. 中华实用儿科临床杂志, 2020, 35(6): 401-410.
http://dx.chinadoi.cn/10.3760/cma.j.cn101070-20191110-01116
|
[2]
|
Doweny Jr., K. (2020) COVID-19 Disrupts Vaccination Efforts, Putting 80 Million Kids at Risk. Infectious Diseases in Children, 2020-05-22
|
[3]
|
王剑虹, 陈锦荣. 全球疫苗与免疫接种现状[J]. 国外医学(预防、诊断、治疗用生物制品分册), 2003, 26(5): 211-212. http://dx.chinadoi.cn/10.3760/cma.j.issn.1673-4211.2003.05.006
|
[4]
|
Ogra, P.L., Faden, H. and Welliver, R.C. (2001) Vaccination Strategies for Mucosal Immune Responses. Clinical Microbiology Reviews, 14, 430-445. https://doi.org/10.1128/CMR.14.2.430-445.2001
|
[5]
|
龚健, 李荣成, 杨进业, 等. 新生儿乙型肝炎疫苗普遍接种的长期免疫效果[J]. 中华肝脏病杂志, 2003, 11(4): 203-205. http://dx.chinadoi.cn/10.3760/j.issn:1007-3418.2003.04.004
|
[6]
|
尹遵栋. 免疫规划发展之路成就与挑战并存[N].健康报, 2020-04-25(4).
|
[7]
|
World Health Organization (n.d.) Vaccine of Hepatitis A. https://www.who.int/ith/vaccines/hepatitisA/en/
|
[8]
|
Wang, X.Y., Xu, Z.Y., Ma, J.C., Lorenz von Seidlein, Yong Zhang, Zhi-Yong Hao, et al. (2007) Long-Term Immunogenicity after Single and Booster Dose of a Live Attenuated Hepatitis A Vaccine: Results from 8-Year Follow-Up. Vaccine, 25, 446-449. https://doi.org/10.1016/j.vaccine.2006.08.004
|
[9]
|
World Health Organization (2014) WHO Informal Consultation on the Scientific Basis of Specifications for Production and Control of Inactivated Japanese Encephalitis Vaccines for Human Use.
https://www.who.int/biologicals/vaccines/japanese_encephalitis/en/
|
[10]
|
李科. 规范接种疫苗为孩子的健康保驾护航[J]. 健康必读, 2020(19): 10.
|
[11]
|
史如松. 20世纪30年代卡介苗接种在中国的实践[J]. 中国医史杂志, 2017, 47(4): 222-225.
http://dx.chinadoi.cn/10.3760/cma.j.issn.0255-7053.2017.04.006
|
[12]
|
卢鹏, 成军, 路希维, 刘二勇, 周林, 陆伟. 科学开展预防性治疗加速遏制结核病进程[J]. 中国防痨杂志, 2020, 42(4): 316-321. http://dx.chinadoi.cn/10.3969/j.issn.1000-6621.2020.04.004
|
[13]
|
戴泉力, 张茂金. 浅谈乙肝的预防与基因工程乙肝疫苗[J]. 科技视野, 2003, 12(3): 44.
http://dx.chinadoi.cn/10.3969/j.issn.1006-4931.2003.02.026
|
[14]
|
肖绍坦, 杨天, 费怡, 邓鹏飞, 杨来宝. 脊髓灰质炎减毒活疫苗和灭活疫苗贯序免疫程序的基础免疫效果[J]. 中国生物制品学杂志, 2020, 33(7): 809-812.
|
[15]
|
Jakinovich, A. and Sood, S.K. (2014) Pertussis: Still a Cause of Death, Seven Decades into Vaccination. Current Opinion in Pediatrics, 26, 597-604. https://doi.org/10.1097/MOP.0000000000000139
|
[16]
|
The PERISCOPE Consortium (2019) PERISCOPE: Road towards Effective Control of Pertussis. Lancet Infect Dis, 19, e179-e186. https://doi.org/10.1016/S1473-3099(18)30646-7
|
[17]
|
Huang, H., Zhu, T., Gao, C., Gao, Z., Liu, Y., Ding, Y., et al. (2015) Epidemiological Features of Pertussis Resurgence Based on Community Populations with High Vaccination Coverage in China. Epidemiology and Infection, 143, 1950-1956. https://doi.org/10.1017/S095026881400260X
|
[18]
|
张兴录, 杨志伟, 周军, 于竞进, 王克安. 我国近年百日咳流行病学特点分析[J]. 中国计划免疫, 2000, 6(2): 93-95. http://dx.chinadoi.cn/10.3969/j.issn.1006-916X.2000.02.011
|
[19]
|
潘殊男, 盛玉博, 肖詹蓉. 中国百日咳疫苗的现状及研发趋势初探[J]. 微生物学免疫学进展, 2012, 40(5): 72-77.
http://dx.chinadoi.cn/10.3969/j.issn.1005-5673.2012.05.016
|
[20]
|
崔雪莲, 吴昕, 黎明强, 李艳萍, 马波, 袁琳. 大规模冻干A+C群脑膜炎球菌多糖结合疫苗接种后安全性观察[J]. 现代预防医学, 2015, 42(1):143-146.
|
[21]
|
秦才珍, 王宏军, 陶红, 等. 不同剂量A/C群脑膜炎球菌多糖结合疫苗免疫学效果评价[J]. 中国疫苗和免疫, 2010, 16(5): 462-465.
|
[22]
|
中华人民共和国卫生部. 扩大国家免疫规划实施方案[Z], 2007-12-29.
|
[23]
|
中华人民共和国卫生部统计信息中心. 2010中国卫生统计年鉴[Z].
|
[24]
|
WHO (2011) Guidelines for Independent Lot Release of Vaccines by Regulatory Authorities.
|
[25]
|
Centers for Disease Control and Prevention (2012) Progress in Global Measles Control, 2000-2010. Morbidity and Mortality Weekly Report, 61, 73-78.
|
[26]
|
夏青娟, 侯丽娟. 甲型肝炎疫苗的使用现状及研究进展[J]. 国际生物制品学杂志, 2017, 40(3): 130-133.
http://dx.chinadoi.cn/10.3760/cma.j.issn.1673-4211.2017.03.006
|
[27]
|
陈琳, 陈立. 甲型肝炎疫苗应用现状及研究进展[J]. 医学综述, 2012, 18(17): 2802-2804.
|
[28]
|
黄建华, 蒙世庭. 甲型病毒性肝炎流行病学研究进展[J]. 实用预防医学, 2012, 19(5): 799-801, 封3.
|
[29]
|
郑徽. 甲型肝炎减毒活疫苗与灭活疫苗免疫原性及其影响因素[J]. 中国疫苗和免疫, 2009, 15(4): 371-374.
|
[30]
|
裴迎新, 曾光. 7价肺炎球菌多糖结合疫苗对全球肺炎球菌疾病的影响[J]. 中国疫苗和免疫, 2014, 20(5): 465-472.
|
[31]
|
World Health Organization (2012) Pneumococcal Vaccines WHO Position Paper-2012. The Weekly Epidemiological Record, 87, 129-144.
|
[32]
|
World Health Organization (2017) Estimates of Disease Burden and Cost Effectiveness.
http://www.who.int/immunization/monitoring_surveillance/burden/estimates/en/
|
[33]
|
Koh, W.M., Bogich, T., Siegel, K., Jin, J., Chong, E.Y., Tan, C.Y., et al. (2016) The Epidemiology of Hand, Foot and Mouth Disease in Asia: A Systematic Review and Analysis. Pediatric Infectious Disease Journal, 35, e285-e300.
https://doi.org/10.1097/INF.0000000000001242
|
[34]
|
Chong, P., Liu, C.C., Chow, Y.H., Chou, A.-H. and Klein, M. (2015) Review of Enterovirus 71 Vaccines. Clinical Infectious Diseases, 60, 797-803. https://doi.org/10.1093/cid/ciu852
|
[35]
|
Mao, Q.Y., Wang, Y., Bian, L., Xu, M. and Liang, Z.L. (2016) EV71 Vaccine, a New Tool to Control Outbreaks of Hand, Foot and Mouth Disease (HFMD). Expert Review of Vaccines, 15, 599-606.
https://doi.org/10.1586/14760584.2016.1138862
|
[36]
|
World Health Organization (2007) WHO Position Paper on Rotavirus Vaccines. The Weekly Epidemiological Record, No. 40, 285-295.
|
[37]
|
Kirkwood, C.D., Gentscb, J.R., Hosbiuo, Y., Fred Clark, H. and Glass, R.I. (1999) Ganutic and Antigenic Characterization of a Serotype P6G9 Human Rotavirus strain Isolated in the United States. Virology, 256, 45-53.
https://doi.org/10.1006/viro.1998.9591
|
[38]
|
朱启镕, 杨永弘, 刁连东. 中国b型流感嗜血杆菌疾病及其免疫预防研讨会会议纪要[J]. 中华传染病杂志, 2005, 23(6): 434-435. http://dx.chinadoi.cn/10.3760/j.issn:1000-6680.2005.06.023
|
[39]
|
Arvin, A.M. and Gilden, D. (2013) Varicella-Zoster Virus. In: Knipe, D.M., Howley, P.M., Eds., Fields Virology, Vol. 2, 6th Edition, Lippincott Williams &Wilkins, Philadelphia, 2015-2058.
|
[40]
|
Freer, G. and Pistello, M. (2018) Varicella-Zoster Virus Infection: Natural History, Clinical Manifestations, Immunity and Current and Future Vaccination Strategies. New Microbiologica, 41, 95-105.
|
[41]
|
Yip, C.C., Lau, S.K., Woo, P.C. and Yuen, K.Y. (2013) Human Enterovirus 71 Epidemics: What’s Next. Emerging Health Threats Journal, 6, Article No. 19780. https://doi.org/10.3402/ehtj.v6i0.19780
|
[42]
|
Chen, B., Sumi, A., Toyoda, S., Hu, Q., Zhou, D.J., Mise, K., et al. (2015) Time Series Analysis of Reported Cases of Hand, Foot, and Mouth Disease from 2010 to 2013 in Wuhan, China. BMC Infectious Diseases, 15, Article No. 495.
https://doi.org/10.1186/s12879-015-1233-0
|
[43]
|
Bian, L., Wang, Y., Yao, X., Mao, Q.Y., Xu, M. and Liang, Z.L. (2015) Coxsackievirus A6: A New Emerging Pathogen Causing Hand, Foot and Mouth Disease Outbreaks Worldwide. Expert Review of Anti-Infective Therapy, 13, 1061-1071. https://doi.org/10.1586/14787210.2015.1058156
|
[44]
|
Centers for Disease Control and Prevention (2012) Notes from the Field: Severe Hand, Foot, and Mouth Disease Associated with Coxsackievirus A6-Alabama, Connecticut, California, and Nevada, November 2011-February 2012. Morbidity and Mortality Weekly Report, 61, 213-214.
|
[45]
|
Puenpa, J., Mauleekoonphairoj, J., Linsuwanon, P., Suwannakarn, K., Chieochansin, T., Korkong, S., et al. (2014) Prevalence and Characterization of Enterovirus Infections among Pediatric Patients with Hand Foot Mouth Disease, Herpangina and Influenza like Illness in Thailand, 2012. PLoS ONE, 9, e98888.
https://doi.org/10.1371/journal.pone.0098888
|
[46]
|
Cabrerizo, M., Tarragod, Munoz-Almagro, C., del Amo, E., Domínguez-Gil, M., Eiros, J.M., et al. (2014) Molecular Epidemiology of Enterovirus 71, Coxsackievirus A16 and A6 Associated with Hand, Foot and Mouth Disease in Spain. Clinical Microbiology and Infection, 20, O150-O156. https://doi.org/10.1111/1469-0691.12361
|
[47]
|
Fonseca, M.C., Sarmiento, L., Resik, S., Martínez, Y., Hung, L.H., Morier, L., et al. (2014) Coxsackievirus A6 and Enterovirus 71 Causing Hand, Foot and Mouth Disease in Cuba, 2011-2013. Archives of Virology, 159, 2451-2455.
https://doi.org/10.1007/s00705-014-2071-x
|
[48]
|
Aswathyraj, S., Arunkumar, G., Alidjinou, E.K. and Hober, D. (2016) Hand, Foot and Mouth Disease (HFMD): Emerging Epidemiology and the Need for a Vaccine Strategy. Medical Microbiology and Immunology, 205, 397-407.
https://doi.org/10.1007/s00430-016-0465-y
|
[49]
|
杨晓明. 联合接种和联合疫苗研究近展[J]. 中国流行病学杂志, 2020(1): 120-122.
|
[50]
|
Anne, I.M. (2017) DNA Vaccines: Regulatory Considerations and Safety Aspects. Current Issues in Molecular Biology, 22, 79-88. https://doi.org/10.21775/cimb.022.079
|
[51]
|
王雨辰, 董寿堂. 基因工程疫苗的研究进展[J]. 科技创新报, 2011(10): 3-4.
|
[52]
|
张雪海, 李娜, 张双凤, 夏时畅, 张人杰. 我国第二类疫苗接种现状及其影响因素研究进展[J]. 中国预防医学杂志, 2018, 19(7): 548-552. http://dx.chinadoi.cn/10.16506/j.1009-6639.2018.07.015
|